ABBV vs LLY
AbbVie and Lilly (Eli), both Healthcare
Lilly (Eli) is the larger company at $980B against $382B. On trailing earnings LLY is the cheaper of the two at a P/E of 39.5 against 78.1, a gap that is only a bargain if the two are growing at similar rates. Over the past year LLY returned +55% against +27% for ABBV. The RyuScore puts LLY ahead, 63 against 52 out of 100.
| Figure | ABBV | LLY |
|---|---|---|
| Last close | $276 | $1179 |
| Market cap | $382B | $980B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 78.1 | 39.5 |
| Dividend yield | 2.4% | 0.5% |
| 1-year return | +27% | +55% |
| 5-year return | +207% | +418% |
| RyuScoresector-relative, 1–10 | 52/100 | 63/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
AbbVie
Revenue of $17B in Q2 2026, net income $3.6B. Its largest reported line is SKYRIZI, 36% of the disclosed total.
Lilly (Eli)
Revenue of $23B in Q2 2026, net income $7.1B. Its largest reported line is Cardiometabolic Health, 47% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.